DailyStocks Stock Article Search

https://seekingalpha.com/news/4089263-jefferies-cuts-instill-bio-to-hold-cites-drug-discontinuation?source=feed_sector_healthcare Apr 12, 2024 - Jefferies downgraded Instil Bio (TIL) to hold, citing discontinuation of clinical development for the company’s drug candidate ITIL-306. 0

https://seekingalpha.com/article/4683358-bruker-offers-upside-with-key-enabling-technologies-for-future-bio-pharma-research?source=feed_all_articles Apr 11, 2024 - Bruker offers growth at reasonable price for investors and is well-positioned for healthy revenue growth in 2024. Find out why BRKR stock is a Buy. 0

https://seekingalpha.com/news/4088992-oppenheimer-starts-q32-bio-at-outperform-cites-lead-asset?source=feed_sector_healthcare Apr 11, 2024 - Oppenheimer started coverage of Q32 Bio (QTTB) with an outperform rating, citing the market potential of the company’s lead drug asset, bempikibart. Read more here. 0

https://www.zacks.com/stock/news/2253383/does-belite-bio-blte-have-the-potential-to-rally-41-14-as-wall-street-analysts-expect?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2253383 Apr 10, 2024 - The consensus price target hints at a 41.1% upside potential for Belite Bio (BLTE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. 0

https://www.zacks.com/stock/news/2252481/here-s-why-you-should-invest-in-entera-bio-entx-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2252481 Apr 09, 2024 - Here, we discuss some reasons why buying Entera Bio (ENTX) stock now may turn out to be a prudent move. 0

https://www.zacks.com/stock/news/2251973/wall-street-analysts-see-a-218-92-upside-in-annovis-bio-anvs-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2251973 Apr 08, 2024 - The average of price targets set by Wall Street analysts indicates a potential upside of 218.9% in Annovis Bio (ANVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. 0

https://www.zacks.com/stock/news/2251859/down-63-39-in-4-weeks-here-s-why-gritstone-bio-grts-looks-ripe-for-a-turnaround?cid=CS-ZC-FT-tale_of_the_tape|rsi-2251859 Apr 08, 2024 - Gritstone bio (GRTS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. 0

https://seekingalpha.com/article/4682514-gritstone-bio-granite-cancer-vaccine-data-overshadowed-by-offering?source=feed_all_articles Apr 06, 2024 - Gritstone bio's GRANITE program shows promise in treating metastatic microsatellite stable colorectal cancer. Read why GRTS stock is a Buy. 0

https://seekingalpha.com/news/4087581-bristol-myers-2seventy-bio-receive-fda-approval-for-abecma-to-treat-multiple-myeloma?source=feed_sector_healthcare Apr 05, 2024 - The CAR T therapy Abecma has been approved for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy. Read more here. 0

https://www.zacks.com/stock/news/2250503/does-kala-bio-kala-have-the-potential-to-rally-152-83-as-wall-street-analysts-expect?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2250503 Apr 04, 2024 - The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. 0